Results 171 to 180 of about 37,430 (216)

Comparative efficacy and safety of pharmacological treatments for lower-risk myelodysplastic syndromes: a Systematic Review and network meta-analysis. [PDF]

Front Oncol
Zhang H, Hu J, Jiang Y, Deng L, Liu S.
europepmc   +1 more source

Population Pharmacokinetics and Model-Informed Precision Dosing of Lenalidomide Incorporating Total and Unbound Plasma Concentrations in Renally Impaired Patients with Multiple Myeloma. [PDF]

Drug Des Devel Ther
Kim H, Park SS, Choi S, Han S, Han S, Lee Y, Lee JH, Kim D, Kim H, Yang S, Shugg T, Chung EK.   +11 more
europepmc   +1 more source

RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma. [PDF]

Blood Adv
Botto B, Boccomini C, Evangelista A, Zilioli VR, Anastasia A, Cavallo F, Merli F, Zanni M, Tani M, Chiarenza A, Liberati AM, Conconi A, Rusconi C, Bari A, Del Giudice I, Gaidano G, Spina M, Maschio N, Castellino C, Rota-Scalabrini D, Puccini B, Arcari A, Bigliardi S, Matta G, Bianchi B, Mannina D, Marino D, Galieni P, Ciambelli F, Musuraca G, Muzi C, Bottelli C, Genuardi E, Meli E, Ferrero S, Luminari S, Ladetto M, Ciccone G, Vitolo U.   +38 more
europepmc   +1 more source

Optimizing CRBN-ligands for optical targeted protein degradation. [PDF]

RSC Med Chem
Flores JA, DiNardi RG, Burslem GM, Cheng T, Trauner DH.   +4 more
europepmc   +1 more source

CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation.

Blood
Minnie SA, Ho K, Boiko JR, Adams RC, Ensbey KS, Nemychenkov NS, Legg SRW, Schmidt CR, Comstock ML, Lyons JM, Sekiguchi T, Koyama M, Spencer A, Green DJ, Hill GR.   +14 more
europepmc   +1 more source